Skip to main content

Table 3 Prioritised research projects for 2018, 2019 and 2020

From: International severe asthma registry (ISAR): protocol for a global registry

Project Investigator
2018
Biologics in severe asthma: utilisation patterns, causes for discontinuation and switching and adverse outcomes Professor Andrew Menzies-Gow (UK)
Hidden severe asthma patients in primary care vs. ISAR Professor David Price (Singapore)
Relationship between socioeconomic status and asthma outcomes Professor Liam Heaney (UK)
The impact of exacerbation burden on lung function trajectory in a broad asthma population and severe asthma population Professor Liam Heaney (UK)
Biomarker Relatability in the International Severe Asthma Registry (BRISAR) Dr. Eve Denton and Dr. Mark Hew (Australia)
Identification of predictors (i.e. biomarkers) of response to biologics Dr. Eve Denton and Dr. Mark Hew (Australia)
Hidden chronic asthma within the COPD/ACO population Professor Chin Kook Rhee (South Korea)
Age of onset of asthma in severe asthma patients Dr. Enrico Heffler (Italy)
2019
Describe the OCS landscape: annual consumption, prevalence, outcomes and side effects of long-term OCS users
Criteria for choosing and switching between similar biological treatment options in patients with atopic and non-atopic severe eosinophilic asthma
2020
What is the impact of co-morbidity in severe asthma?
Define responders and non-responders to biologics and describe their characteristics overall and per biologic
Describe the clinical outcome before and after biologic treatment by biologic class, by individual biologic, and by subgroups of baseline characteristics
  1. ACO asthma-chronic obstructive pulmonary disease overlap, COPD chronic obstructive pulmonary disease, FEV1 forced expiratory volume in 1 second, ISAR International Severe Asthma Registry, OCS oral corticosteroids, UK United Kingdom